NON-NUCLEASE BASED GENE EDITING FOR HUTCHINSON-GILFORD PROGERIA
针对 Hutchinson-Gilford 早衰症的非核酸基因编辑
基本信息
- 批准号:10323044
- 负责人:
- 金额:$ 24.72万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-01-01 至 2022-12-31
- 项目状态:已结题
- 来源:
- 关键词:14 year oldAffectAgeAgingAnemiaAortaAtherosclerosisBindingBiomechanicsBlood PressureCardiovascular systemCause of DeathCellsCentral ArteryChemicalsChemistryChildChildhoodChromosomesClinical TrialsClustered Regularly Interspaced Short Palindromic RepeatsCollaborationsComplexDNADNA BindingDNA DamageDNA RepairDNA Sequence RearrangementDataDevelopmentDiseaseEnrollmentExtramedullary HematopoiesisFailureFormulationFoundationsFrequenciesFunctional disorderGenerationsGenesGeneticGenetic DiseasesGenetic RecombinationGenomeGenomicsGlycolatesHeart failureHematopoietic stem cellsHistologicHomologous GeneHumanHuman GeneticsImmunityIndividualIntravenousIntravenous infusion proceduresLeadLeftLesionLipidsMechanicsMediatingMolecular ConformationMorphologyMusMusculoskeletalMutationNucleic AcidsNylonsPatientsPeptide Nucleic AcidsPhenotypePhysiologic pulsePhysiologicalPoint MutationPositioning AttributePremature MortalityProgeriaPropertyProteinsQuality ControlRNA SplicingReagentResistanceResourcesRiskSafetySiteSmooth Muscle MyocytesSplenomegalyStreptococcus pyogenesSyndromeSystemTechniquesTechnologyTestingTherapeuticTissuesToxic effectVentricularVertebral columnWorkarterial stiffnessbasebeta Globinbeta Thalassemiacarcinogenesisclinical applicationclinical translationclinically relevantdisease-causing mutationgene correctionhomologous recombinationhuman modelimprovedin vivoin vivo evaluationinnovationinterestminimally invasivemortalitymouse modelnanoparticlenovelnucleasenucleic acid analogpre-clinicalsexsynthetic nucleic acidtargeted nucleasestherapeutic genome editingtranscription activator-like effector nucleaseszinc finger nuclease
项目摘要
Project Summary
There is substantial interest in gene editing as a means to treat human genetic disorders such as Hutchinson-
Gilford Progeria Syndrome (HGPS). Much effort has been focused on targeted nucleases such as
CRISPR/Cas9, since site-directed DNA damage strongly promotes homologous recombination (HR). However,
clinical application of targeted nucleases is challenged by the risk of off-target cleavage in the genome, which
can lead to carcinogenesis. As an alternative, we have shown that chemically modified triplex-forming peptide
nucleic acids (TFPs) and donor DNAs (containing corrected base) delivered intravenously (IV) via poly(lactic-
co-glycolic) acid (PLGA) nanoparticles into a mouse model of human β-thalassemia produced almost complete
amelioration of the disease, with clinically relevant β-globin gene correction frequencies in hematopoietic stem
cells (HSCs) of up to 7%. TFPs can bind to duplex DNA in a sequence-specific manner and thereby stimulate
DNA repair and recombination. The mice showed alleviation of anemia, improvement in RBC morphologies,
and reversal of splenomegaly and extramedullary hematopoiesis with extremely low off-target effects in the
genome compared to nuclease-based approaches, a key advantage of this technology. The other key
advantage is that the components can be synthesized chemically and formulated into nanoparticles for simple
IV administration. In the proposed work, we will test whether the same technology can be applied with the
same efficiency for editing LMNA point mutation. Herein, our central hypothesis is to establish the feasibility of
a new minimally invasive and innovative therapeutic paradigm for HGPS disease: application of further
advances in nucleic acid chemistry and nanoparticle technology for the site-directed editing of LMNA mutation
in vivo by facile IV infusion with high efficiency and low toxicity. We will pursue two specific aims; Aim 1)
Development of new generation chemically modified PNAs to boost gene editing at the LMNA mutation site
and in Aim 2) To test the gene editing efficiency at LMNA mutation site in vivo by simple IV infusion of PLGA
NP. This work will lay the foundation for a novel gene editing therapy for HGPS that has a high efficiency and
much lower risk of off-target effects compared to existing nuclease based approaches.
项目摘要
人们对基因编辑作为治疗人类遗传性疾病的一种手段非常感兴趣,例如哈钦森-
吉尔福德早衰综合征(HGPS)。许多努力都集中在靶向核酸酶上,
CRISPR/Cas9,因为定点DNA损伤强烈促进同源重组(HR)。然而,在这方面,
靶向核酸酶的临床应用受到基因组中脱靶切割风险的挑战,
会导致致癌。作为替代方案,我们已经表明,化学修饰的三链体形成肽
核酸(TFP)和供体DNA(含有校正的碱基)通过聚(乳酸-
共-羟基乙酸(PLGA)纳米颗粒进入人β-地中海贫血小鼠模型产生了几乎完全
改善疾病,造血干细胞中临床相关的β-珠蛋白基因校正频率
细胞(HSC)高达7%。TFP可以以序列特异性的方式结合双链体DNA,从而刺激DNA的合成。
DNA修复和重组。小鼠表现出贫血的缓解,RBC形态的改善,
以及脾肿大和髓外造血的逆转,
与基于核酸酶的方法相比,这是该技术的一个关键优势。另一个关键
其优点是,组分可以化学合成并配制成纳米颗粒,
IV给药。在拟议的工作中,我们将测试是否可以将相同的技术应用于
编辑LMNA点突变的效率相同。在这里,我们的中心假设是建立的可行性,
一种新的微创和创新的治疗HGPS疾病的范例:应用进一步
用于LMNA突变定点编辑的核酸化学和纳米颗粒技术的进展
在体内通过简单的IV输注进行,具有高效和低毒性。我们将追求两个具体目标:目标1)
开发新一代化学修饰的PNA以促进LMNA突变位点的基因编辑
目的2)通过PLGA的简单IV输注来测试体内LMNA突变位点处的基因编辑效率
NP.这项工作将为HGPS的新型基因编辑疗法奠定基础,该疗法具有高效,
与现有的基于核酸酶的方法相比,脱靶效应的风险低得多。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DEMETRIOS BRADDOCK其他文献
DEMETRIOS BRADDOCK的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DEMETRIOS BRADDOCK', 18)}}的其他基金
ENZYME THERAPY FOR CKD-MBD: BREAKING THE BARRIER OF VASCULAR CALCIFICATION
CKD-MBD 酶疗法:打破血管钙化障碍
- 批准号:
10348745 - 财政年份:2020
- 资助金额:
$ 24.72万 - 项目类别:
ENZYME THERAPY FOR CKD-MBD: BREAKING THE BARRIER OF VASCULAR CALCIFICATION
CKD-MBD 酶疗法:打破血管钙化障碍
- 批准号:
9891444 - 财政年份:2020
- 资助金额:
$ 24.72万 - 项目类别:
LOCATING THE REGIONS OF AN ADML 3' INTRON RNA ANALOGUE BOUND TO PUF60 RRMS
定位与 PUF60 RRMS 结合的 ADML 3 内含子 RNA 类似物的区域
- 批准号:
8363546 - 财政年份:2011
- 资助金额:
$ 24.72万 - 项目类别:
3D DETERMINATION OF AN NPASE PHOSPHODIESTERASE
NPASE 磷酸二酯酶的 3D 测定
- 批准号:
8171514 - 财政年份:2010
- 资助金额:
$ 24.72万 - 项目类别:
3D DETERMINATION OF AN NPASE PHOSPHODIESTERASE
NPASE 磷酸二酯酶的 3D 测定
- 批准号:
7721317 - 财政年份:2008
- 资助金额:
$ 24.72万 - 项目类别:
相似海外基金
Hormone therapy, age of menopause, previous parity, and APOE genotype affect cognition in aging humans.
激素治疗、绝经年龄、既往产次和 APOE 基因型会影响老年人的认知。
- 批准号:
495182 - 财政年份:2023
- 资助金额:
$ 24.72万 - 项目类别:
Investigating how alternative splicing processes affect cartilage biology from development to old age
研究选择性剪接过程如何影响从发育到老年的软骨生物学
- 批准号:
2601817 - 财政年份:2021
- 资助金额:
$ 24.72万 - 项目类别:
Studentship
RAPID: Coronavirus Risk Communication: How Age and Communication Format Affect Risk Perception and Behaviors
RAPID:冠状病毒风险沟通:年龄和沟通方式如何影响风险认知和行为
- 批准号:
2029039 - 财政年份:2020
- 资助金额:
$ 24.72万 - 项目类别:
Standard Grant
Neighborhood and Parent Variables Affect Low-Income Preschool Age Child Physical Activity
社区和家长变量影响低收入学龄前儿童的身体活动
- 批准号:
9888417 - 财政年份:2019
- 资助金额:
$ 24.72万 - 项目类别:
The affect of Age related hearing loss for cognitive function
年龄相关性听力损失对认知功能的影响
- 批准号:
17K11318 - 财政年份:2017
- 资助金额:
$ 24.72万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
9320090 - 财政年份:2017
- 资助金额:
$ 24.72万 - 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
10166936 - 财政年份:2017
- 资助金额:
$ 24.72万 - 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
9761593 - 财政年份:2017
- 资助金额:
$ 24.72万 - 项目类别:
How age dependent molecular changes in T follicular helper cells affect their function
滤泡辅助 T 细胞的年龄依赖性分子变化如何影响其功能
- 批准号:
BB/M50306X/1 - 财政年份:2014
- 资助金额:
$ 24.72万 - 项目类别:
Training Grant
Inflamm-aging: What do we know about the effect of inflammation on HIV treatment and disease as we age, and how does this affect our search for a Cure?
炎症衰老:随着年龄的增长,我们对炎症对艾滋病毒治疗和疾病的影响了解多少?这对我们寻找治愈方法有何影响?
- 批准号:
288272 - 财政年份:2013
- 资助金额:
$ 24.72万 - 项目类别:
Miscellaneous Programs